Cor­rect­ed: En­tra­da rais­es $100M for Duchenne de­vel­op­ment; eF­FEC­TOR winds down

Plus, news about Neu­roBo, Vi­co Ther­a­peu­tics, Take­da, Check­point Ther­a­peu­tics, Com­bi­Gene, Spark Ther­a­peu­tics, ANI, Al­imera Sci­ences and OSE Im­munother­a­peu­tics:

En­tra­da Ther­a­peu­tics rais­es $100M from stock sale …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.